Barclays Sticks to Their Buy Rating for Teva Pharmaceutical (TEVA)
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
BioPharma Dive18h
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...
FiercePharma20h
Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...
3 Growth Stocks That Could Skyrocket in 2025 and Beyond
Growth stocks can help to supercharge your investment portfolio and boost your retirement fund. The key, however, is to ...
centerforbiosimilars8h
3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Future Market Insights17h
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Set to Reach USD 47,045.80 Million by 2034 at a 3.6% of CAGR
The global benign prostatic hyperplasia (BPH) prostate treatment market is projected to grow from USD 33.03 billion in 2024 ...